Search for: "In re: Lamictal Direct Purchaser Antitrust Litigation" Results 1 - 4 of 4
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
29 May 2020, 5:00 am by Carolyn Casey, J.D.
The case, In re Lamictal Direct Purchaser Antitrust Litigation, is a stark reminder for litigators that relying on the “common questions of law or fact” for class certification is not always an adequate argument in the eyes of the court. [read post]
23 Oct 2012, 6:30 am by Matthew Gilpin
 Sources[1] Federal Trade Commission Brief as Amicus Curiae, In re Lamictal Direct Purchaser Antitrust Litig., No. 2:12-cv-00995 (D.N.J. [read post]
19 Jun 2015, 11:04 am by Robert Reznick
.,[1] resolved long-running antitrust litigation stemming from four “reverse payment” settlements of Hatch-Waxman patent infringement cases involving the branded drug Provigil®. [read post]